NCT04544462View on ClinicalTrials.gov

ANXA5 M2 Haplotyping in IVF Patients and Embryos

Active, not recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
InfertilityMiscarriage, RecurrentPregnancy Complications
Interventions
OTHER

M2 Test

DNA will be extracted from saliva samples obtained from participants. Genetic testing will be performed to screen for the M2 mutation and determine the carrier status of each patient and partner.

Trial Locations (1)

08902

Genomic Prediction Clinical Laboratory, North Brunswick

Sponsors
All Listed Sponsors
lead

Genomic Prediction Inc.

INDUSTRY

NCT04544462 - ANXA5 M2 Haplotyping in IVF Patients and Embryos | Biotech Hunter | Biotech Hunter